Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens

G. Cornaglia, G. M. Rossolini

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA β-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature.

Original languageEnglish
Pages (from-to)218-223
Number of pages6
JournalClinical Microbiology and Infection
Volume15
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Anti-Bacterial Agents
Glycopeptides
Methicillin-Resistant Staphylococcus aureus
Infection
oritavancin
Lactams
Enterococcus
Multiple Drug Resistance
Therapeutics
Italy
Pharmaceutical Preparations
dalbavancin
ceftobiprole
iclaprim
telavancin

Keywords

  • Antimicrobial agents
  • Gram-positive pathogens
  • Multidrug resistance
  • Review

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. / Cornaglia, G.; Rossolini, G. M.

In: Clinical Microbiology and Infection, Vol. 15, No. 3, 2009, p. 218-223.

Research output: Contribution to journalArticle

@article{8f68db7644784497ba05bd97491cda69,
title = "Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens",
abstract = "Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA β-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature.",
keywords = "Antimicrobial agents, Gram-positive pathogens, Multidrug resistance, Review",
author = "G. Cornaglia and Rossolini, {G. M.}",
year = "2009",
doi = "10.1111/j.1469-0691.2009.02740.x",
language = "English",
volume = "15",
pages = "218--223",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens

AU - Cornaglia, G.

AU - Rossolini, G. M.

PY - 2009

Y1 - 2009

N2 - Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA β-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature.

AB - Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA β-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature.

KW - Antimicrobial agents

KW - Gram-positive pathogens

KW - Multidrug resistance

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=63249105066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249105066&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2009.02740.x

DO - 10.1111/j.1469-0691.2009.02740.x

M3 - Article

VL - 15

SP - 218

EP - 223

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 3

ER -